Fairvalue-Calculator Fairvalue-Calculator
EN DE

Huadong Medicine Co (000963) Fair Value & Analysis

Healthcare · CN · Market cap 50.9B CNY

Price¥28.78
Fair Value¥42.83
Upside+48.8%
Quality94/100
Evidence: High Range ¥28.91 – ¥53.54

Fair value as of: Jun 25, 2026

Analysis

Huadong Medicine Co (000963) currently trades at ¥28.78, while our model-based Fair Value estimate is ¥42.83 — implying the stock looks roughly 48.8% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Huadong Medicine Co., Ltd, together with its subsidiaries, engages in the wholesale and retail of pharmaceutical products in China and internationally. The company operates through Pharmaceutical Manufacturing, Pharmaceutical Distribution, Medical Aesthetics, and Industrial Microbiology segments. It offers Chinese medicine, immunosuppressive agents, endocrine, digestive system, antineoplastic, cardiovascular, antibiotic drugs, medical beauty field, and medical devices, as well as engages in pharmaceutical logistics and industrial microbiology activities. In addition, the company provides formulation filling, technical, transportation and warehousing services. Huadong Medicine Co., Ltd was incorporated in 1993 and is headquartered in Hangzhou, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Huadong Medicine Co (000963) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥42.83 versus a price of ¥28.78 — about +49% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 000963?
Our 21-model fair value for Huadong Medicine Co is ¥42.83 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥28.78.
What is the quality score of 000963?
Huadong Medicine Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.